Metabolic & Cardiometabolic

ezetimibe prevents cholesterol gallstones

In plain terms: Does the cholesterol drug ezetimibe prevent gallstones?

Insufficient(Laboratory findings not confirmed in people) Metabolic & Cardiometabolic 🐭 Non-human evidence🔬 Includes disconfirming

Part of: 💊 ezetimibe

RefutedContestedStrong support

consensus score 0.69

⚖️ Thin evidence — read the needle loosely. The score shows which way the studies lean, but there are too few independent, high-quality ones to place it firmly. Expect this to move as better evidence arrives.

Why the rating is limited: laboratory findings not confirmed in people.

The studies supporting this claim are animal or laboratory studies. Human studies have tested it without finding the claimed effect, or have found evidence against it.

Before this limit: strong support. Final rating: insufficient.

Not in people. Animal studies hint at it, but two large genetic studies that mimic the drug's action found no protection against gallstones in humans. A speculative possible side-benefit, not an established one.

🧭 Read this score with how it was built in mindLab and animal results no longer outvote a human study that found nothing

Five animal and mechanism studies support it; two large genetic studies that mimic the drug in people found no protection against gallstones.

📅 Last reviewed: 2026-07-15 ⓘ

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: Animal studies (Animal)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

5 support 0 contradict 2 tested null 0 mixed · 7 sources, 5 independent groups

What the evidence shows

Ezetimibe prevents cholesterol gallstone formation in mice by desaturating biliary cholesterol (direct NPC1L1 mechanism) - reproducible and mechanistically coherent, but not borne out in people: two Mendelian-randomisation studies that mimic NPC1L1 inhibition found no protection against gallstones, and there is no human outcome trial. Plausible in mice, not established in people.

The evidence (7)

Source	Grade	Stance	Quality	Finding
Wang HH, Portincasa P, Mendez-Sanchez N, Uribe M, Wang DQ 2008 · Gastroenterology	animal	supports	moderate	Wittenburg/Wang 2008 mouse lithogenic-diet; human arm measured only biliary cholesterol NOT gallstone outcome; regrade->animal
Mo P, Chen H, Jiang X, Hu F, Zhang F, Shan G, Chen W, Li S, Xu G 2023 · Heliyon	animal	supports	moderate	AAV-mNPC1L1 mice EZE prevents cholesterol gallstone via biliary desaturation; 3rd animal group no human
Yang G, Mason AM, Gill D, Schooling CM, Burgess S 2024 · Eur J Epidemiol	observational	tested-null	low	Drug-target Mendelian randomization, UK Biobank (30,547 gallstone cases), FinnGen (34,461) and Biobank Japan (9,305); NPC1L1 variants mimic ezetimibe (European ancestry only - no usable NPC1L1 instruments in East Asians). Ezetimibe is not among the targets reported as associated: statins lowered risk (OR 0.72, 0.62-0.83 per 1-SD LDL reduction) while PCSK9, apoB and ABCG5/8 mimics raised it. The NPC1L1 estimate appears only in Fig. 1, so whether it is a clean null or a trend is cannot-tell from available text; the MR-Egger intercept flagged 'possible directional pleiotropy for ezetimibe (UK Biobank)' (p=0.002). Outcome is all gallstone disease, not specifically cholesterol stones; lifelong genetic proxy, not drug treatment.
Dong H, Chen R, Xu F, Cheng F 2024 · Clinical epidemiology	observational	tested-null	moderate	Human Mendelian randomization study of genetically-proxied lipid-lowering drug targets (HMGCR, PCSK9, NPC1L1) vs cholelithiasis risk; NPC1L1 inhibition (ezetimibe's mechanism) showed no significant correlation with cholelithiasis risk in ei
Sun Y, Fan Z, Zhu X, Xia C, Shen G 2025 · Food science and biotechnology	animal	supports	moderate	Mouse lithogenic-diet model; ezetimibe (5 mg/day, positive control) suppressed cholesterol gallstone formation and reduced bile cholesterol/phospholipids alongside sodium butyrate. Confirms known ezetimibe anti-lithogenic effect in mice.
Shen W, Shao W, Wang Q, Wang B, Zhao G, Gu A, Jiang Z, Hu H 2023 · Journal of biomedical science	animal	supports	moderate	Mouse lithogenic-diet model comparing diosgenin to ezetimibe; ezetimibe supplementation completely prevented gallstone formation via NPC1L1 downregulation/cholesterol absorption inhibition. Ezetimibe is the established comparator drug in th
Zúñiga S, Molina H, Azocar L, Amigo L, Nervi F, Pimentel F, Jarufe N, Arrese M, Lammert F, Miquel JF 2008 · Liver Int	animal	supports	moderate	Zuniga 2008 EZE prevents gallstones C57BL/6 mice 60% drop CSI NPC1L1 mechanism. ANIMAL

Disagree, or know a study we missed?

We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.

📚 Suggest a study ⚑ Flag / request reclassification

Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.